301075 多瑞医药
已收盘 03-24 15:00:00
资讯
新帖
简况
3月24日多瑞医药现1笔折价24.37%的大宗交易 合计成交1416万元
证券之星 · 03-24 17:01
3月24日多瑞医药现1笔折价24.37%的大宗交易 合计成交1416万元
多瑞医药（301075）披露2026年第一次临时股东大会通知，3月17日股价上涨0.18%
证券之星 · 03-17
多瑞医药（301075）披露2026年第一次临时股东大会通知，3月17日股价上涨0.18%
多瑞医药（301075）披露持股5%以上股东部分股份解除质押公告，3月12日股价下跌3.24%
证券之星 · 03-12
多瑞医药（301075）披露持股5%以上股东部分股份解除质押公告，3月12日股价下跌3.24%
多瑞医药（301075）披露减持回购股份比例达到1%的进展公告，3月9日股价上涨7.95%
证券之星 · 03-09
多瑞医药（301075）披露减持回购股份比例达到1%的进展公告，3月9日股价上涨7.95%
多瑞医药（301075）披露回购股份集中竞价减持进展公告，3月2日股价上涨0.51%
证券之星 · 03-02
多瑞医药（301075）披露回购股份集中竞价减持进展公告，3月2日股价上涨0.51%
多瑞医药（301075）披露王庆太、曹晓兵要约收购股份完成过户公告，2月27日股价上涨16.22%
证券之星 · 02-27
多瑞医药（301075）披露王庆太、曹晓兵要约收购股份完成过户公告，2月27日股价上涨16.22%
多瑞医药最新公告：王庆太、曹晓兵要约收购期满股票复牌
证券之星 · 02-26
多瑞医药最新公告：王庆太、曹晓兵要约收购期满股票复牌
多瑞医药：要约收购期限届满 股票自2月25日起停牌
新京报 · 02-24
多瑞医药：要约收购期限届满 股票自2月25日起停牌
多瑞医药宣布2月25日起停牌 以待要约收购结果出炉
美股速递 · 02-24
多瑞医药宣布2月25日起停牌 以待要约收购结果出炉
新实控人入主后，多瑞医药一月内接连注销两家子公司
新京报 · 02-12
新实控人入主后，多瑞医药一月内接连注销两家子公司
新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎
21世纪经济报道 · 02-12
新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎
多瑞医药最新公告：王庆太、曹晓兵拟要约收购公司24.30%股份
证券之星 · 02-10
多瑞医药最新公告：王庆太、曹晓兵拟要约收购公司24.30%股份
多瑞医药（301075）披露王庆太、曹晓兵要约收购公司股份的第一次提示性公告，1月30日股价下跌0.29%
证券之星 · 01-30
多瑞医药（301075）披露王庆太、曹晓兵要约收购公司股份的第一次提示性公告，1月30日股价下跌0.29%
核心产品销量及售价大幅下滑，多瑞医药2025年净利润预亏
新京报 · 01-30
核心产品销量及售价大幅下滑，多瑞医药2025年净利润预亏
多瑞医药（301075）披露2025年度业绩预告，1月29日股价下跌4.71%
证券之星 · 01-29
多瑞医药（301075）披露2025年度业绩预告，1月29日股价下跌4.71%
股市必读：1月13日多瑞医药发生1笔大宗交易 成交金额696.13万元
证券之星 · 01-14
股市必读：1月13日多瑞医药发生1笔大宗交易 成交金额696.13万元
多瑞医药（301075）披露关于要约收购提示性公告期满90日的说明，1月12日股价上涨0.41%
证券之星 · 01-12
多瑞医药（301075）披露关于要约收购提示性公告期满90日的说明，1月12日股价上涨0.41%
多瑞医药（301075）披露关于注销募集资金专项账户的公告，1月9日股价下跌1.64%
证券之星 · 01-09
多瑞医药（301075）披露关于注销募集资金专项账户的公告，1月9日股价下跌1.64%
多瑞医药（301075）披露回购股份集中竞价减持计划，12月22日股价下跌1.77%
证券之星 · 2025-12-22
多瑞医药（301075）披露回购股份集中竞价减持计划，12月22日股价下跌1.77%
多瑞医药(301075.SZ)拟出售不超104.45万股已回购股份
智通财经网 · 2025-12-19
多瑞医药(301075.SZ)拟出售不超104.45万股已回购股份
加载更多
公司概况
公司名称：
西藏多瑞医药股份有限公司
所属行业：
医药制造业
上市日期：
2021-09-29
主营业务：
西藏多瑞医药股份有限公司的主营业务是化学药品制剂及中间体、原料药的研发、生产和销售。公司的主要产品是制剂、中间体、原料药。
发行价格：
27.27
{"stockData":{"symbol":"301075","market":"SZ","secType":"STK","nameCN":"多瑞医药","latestPrice":78.01,"timestamp":1774335813000,"preClose":73.74,"halted":0,"volume":1131900,"delay":0,"changeRate":0.0579,"floatShares":80000000,"shares":80000000,"eps":-1.5665,"marketStatus":"已收盘","change":4.27,"latestTime":"03-24 15:00:00","open":76,"high":78.1,"low":75.02,"amount":86684700,"amplitude":0.0418,"askPrice":78.02,"askSize":35,"bidPrice":78.01,"bidSize":20,"shortable":0,"etf":0,"ttmEps":-1.5665,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774402200000},"marketStatusCode":5,"adr":0,"adjPreClose":73.74,"symbolType":"stock","openAndCloseTimeList":[[1774315800000,1774323000000],[1774328400000,1774335600000]],"highLimit":81.11,"lowLimit":66.37,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":80000000,"isCdr":false,"pbRate":9.88,"roa":"--","roe":"--","epsLYR":-0.79,"committee":-0.28,"marketValue":6241000000,"turnoverRate":0.0141,"status":0,"floatMarketCap":6241000000},"requestUrl":"/m/hq/s/301075","defaultTab":"news","newsList":[{"id":"2621050328","title":"3月24日多瑞医药现1笔折价24.37%的大宗交易 合计成交1416万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621050328","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621050328?lang=zh_cn&edition=full","pubTime":"2026-03-24 17:01","pubTimestamp":1774342902,"startTime":"0","endTime":"0","summary":"证券之星消息，3月24日多瑞医药发生大宗交易，交易数据如下：大宗交易成交价格59元，相对当日收盘价折价24.37%，成交24万股，成交金额1416万元，买方营业部为招商证券股份有限公司上海牡丹江路证券营业部，卖方营业部为国联民生证券股份有限公司北京分公司。近三个月该股共发生3笔大宗交易，合计成交4450.0手，折价成交1笔。截至2026年3月24日收盘，多瑞医药报收于78.01元，上涨5.79%，换手率1.41%，成交量1.13万手，成交额8668.47万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400028038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2620847520","title":"多瑞医药（301075）披露2026年第一次临时股东大会通知，3月17日股价上涨0.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620847520","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620847520?lang=zh_cn&edition=full","pubTime":"2026-03-17 22:58","pubTimestamp":1773759493,"startTime":"0","endTime":"0","summary":"截至2026年3月17日收盘，多瑞医药报收于82.91元，较前一交易日上涨0.18%，最新总市值为66.33亿元。该股当日开盘83.0元，最高83.98元，最低81.62元，成交额达9317.79万元，换手率为1.41%。近日，多瑞医药披露《关于召开2026年第一次临时股东会的通知》。股权登记日为2026年3月31日，股东可通过现场或网络投票方式参与表决。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700042437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2618340130","title":"多瑞医药（301075）披露持股5%以上股东部分股份解除质押公告，3月12日股价下跌3.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618340130","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618340130?lang=zh_cn&edition=full","pubTime":"2026-03-12 22:19","pubTimestamp":1773325156,"startTime":"0","endTime":"0","summary":"截至2026年3月12日收盘，多瑞医药报收于87.39元，较前一交易日下跌3.24%，最新总市值为69.91亿元。该股当日开盘89.0元，最高89.5元，最低85.85元，成交额达1.82亿元，换手率为2.61%。多瑞医药于2026年3月12日披露《关于持股5%以上股东部分股份解除质押的公告》。本次解除质押股份合计4,194,408股，占公司总股本的5.24%。本次变动后，西藏嘉康累计质押股份为3,340,000股，占其所持股份的37.40%，占公司总股本的4.18%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200038758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2618622602","title":"多瑞医药（301075）披露减持回购股份比例达到1%的进展公告，3月9日股价上涨7.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618622602","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618622602?lang=zh_cn&edition=full","pubTime":"2026-03-09 22:28","pubTimestamp":1773066502,"startTime":"0","endTime":"0","summary":"截至2026年3月9日收盘，多瑞医药报收于90.52元，较前一交易日上涨7.95%，最新总市值为72.42亿元。该股当日开盘82.88元，最高91.39元，最低82.8元，成交额达2.51亿元，换手率为3.59%。公司于2026年3月9日发布《关于减持回购股份比例达到1%的进展公告》。公司已于2025年12月19日披露减持计划，拟减持数量不超过1,044,500股，减持期间为2026年1月14日至2026年7月13日。减持计划实施存在不确定性，公司将根据市场情况决定具体减持安排。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900035314.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2616535950","title":"多瑞医药（301075）披露回购股份集中竞价减持进展公告，3月2日股价上涨0.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616535950","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616535950?lang=zh_cn&edition=full","pubTime":"2026-03-02 23:31","pubTimestamp":1772465471,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘，多瑞医药报收于74.88元，较前一交易日上涨0.51%，最新总市值为59.9亿元。公司于近日披露《关于回购股份集中竞价减持的进展公告》。公告显示，西藏多瑞医药股份有限公司于2025年12月19日审议通过《关于回购股份集中竞价减持计划的议案》，拟通过集中竞价方式减持已回购股份，数量不超过1,044,500股，占总股本1.31%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200040647.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2614857128","title":"多瑞医药（301075）披露王庆太、曹晓兵要约收购股份完成过户公告，2月27日股价上涨16.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614857128","media":"证券之星","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614857128?lang=zh_cn&edition=full","pubTime":"2026-02-27 23:14","pubTimestamp":1772205256,"startTime":"0","endTime":"0","summary":"公司于2026年2月27日披露《关于王庆太、曹晓兵要约收购公司股份完成过户的公告》。公告显示，西藏多瑞医药股份有限公司于2026年1月21日披露要约收购报告书，王庆太、曹晓兵向除其一致行动人以外的全体股东发出部分要约，拟收购19,440,000股，占总股本24.30%，价格为32.07元/股，要约期限为2026年1月22日至2月24日。截至期限届满，王庆太获3户预受要约股份17,600,600股，曹晓兵获4户预受要约股份1,851,400股，其中西藏嘉康时代科技发展有限公司已预受要约19,440,000股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700043158.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2614016580","title":"多瑞医药最新公告：王庆太、曹晓兵要约收购期满股票复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2614016580","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614016580?lang=zh_cn&edition=full","pubTime":"2026-02-26 17:12","pubTimestamp":1772097151,"startTime":"0","endTime":"0","summary":"多瑞医药(301075.SZ)公告称，王庆太、曹晓兵要约收购期限已届满，收购人及其一致行动人共计持有公司4312万股股份，占总股本的53.90%，公司股权分布仍符合上市条件。公司股票自2026年2月27日起复牌。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600025747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2613747796","title":"多瑞医药：要约收购期限届满 股票自2月25日起停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2613747796","media":"新京报","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613747796?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:01","pubTimestamp":1771923660,"startTime":"0","endTime":"0","summary":"新京报贝壳财经讯 2月24日，多瑞医药公告，公司于2026年1月21日披露了王庆太、曹晓兵送达的《西藏多瑞医药股份有限公司要约收购报告书》，要约价格为32.07元/股，要约收购股份数量1944万股，占公司总股本的24.30%。截至2026年2月24日，本次要约收购期限已届满。公司股票自2026年2月25日(星期三)上午开市起停牌，并将在要约收购结果公告日开市起复牌。","market":"sh","thumbnail":"https://media.bjnews.com.cn/cover/2026/02/06/5683887317140448531.jpeg?x-oss-process=image/resize,m_lfit,w_365","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2026/02/06/5683887317140448531.jpeg?x-oss-process=image/resize,m_lfit,w_365"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1771923377129309.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1771923377129309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"1191201286","title":"多瑞医药宣布2月25日起停牌 以待要约收购结果出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=1191201286","media":"美股速递","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191201286?lang=zh_cn&edition=full","pubTime":"2026-02-24 16:53","pubTimestamp":1771923225,"startTime":"0","endTime":"0","summary":"西藏多瑞医药股份有限公司（以下简称“多瑞医药”）发布公告称，公司股票自2024年2月25日开市起停牌。\n此次停牌旨在等待要约收购的最终结果。待相关事项确定后，公司将及时披露信息并申请股票复牌。市场关注此次要约收购的进展，及其对公司未来战略发展的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2610992190","title":"新实控人入主后，多瑞医药一月内接连注销两家子公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2610992190","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610992190?lang=zh_cn&edition=full","pubTime":"2026-02-12 11:42","pubTimestamp":1770867720,"startTime":"0","endTime":"0","summary":"业内认为，多瑞医药短期内接连注销子公司，一方面是子公司业绩不佳无法为母公司贡献收益，另一方面是新实控人入主后对公司业务的优化与调整。新实控人入主后，能否带领多瑞医药走出亏损，助力其发展，仍有待时间验证。","market":"us","thumbnail":"https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/2/wangl8820262111657492906241.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/2/wangl8820262111657492906241.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1770867741168435.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1770867741168435.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2610960339","title":"新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎","url":"https://stock-news.laohu8.com/highlight/detail?id=2610960339","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610960339?lang=zh_cn&edition=full","pubTime":"2026-02-12 07:27","pubTimestamp":1770852424,"startTime":"0","endTime":"0","summary":"这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！政策动向国家卫健委等11部门联合印发《国家基本药物目录管理办法》2月11日，国家卫生健康委等联合印发《国家基本药物目录管理办法》。与原有的文件相比，《国家基本药物目录管理办法》主要修订六个方面：一是增加法律政策依据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602123648366353.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602123648366353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","BK0012","LU2495084118.USD","300683","LU0405327148.USD","LU1820825898.SGD","LU1997245177.USD","LU2580892862.HKD","601607","BK0175","BK0187","LU2148510915.USD","BK0097","BK0046","300142","BK0183","BK0060","LU2289578879.USD","600276","LU1580142542.USD","LU2580892789.USD","LU2097828474.EUR","LU2097828631.EUR","LU2328871848.SGD","LU1997244956.HKD","BK0209","LU2097828557.USD","LU1655091616.SGD","LU1969619763.USD","BK0239","LU0405327494.USD","BK0188","LU1781817850.SGD","LU1997245094.SGD","BK0028","BK0077","LU1064131003.USD","BK0184","BK0020","BK0070","BK0099","BK0196","LU2097828805.USD","LU1328615791.USD","LU1146622755.USD","301075","LU2097828714.EUR","LU1255011170.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2610662972","title":"多瑞医药最新公告：王庆太、曹晓兵拟要约收购公司24.30%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2610662972","media":"证券之星","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610662972?lang=zh_cn&edition=full","pubTime":"2026-02-10 23:00","pubTimestamp":1770735635,"startTime":"0","endTime":"0","summary":"多瑞医药(301075.SZ)公告称，王庆太、曹晓兵拟通过部分要约的方式，按照32.07元/股的价格向除崔子浩外的全体股东发出部分要约收购，初步要约比例分别为22%、2.30%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000038571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2607423000","title":"多瑞医药（301075）披露王庆太、曹晓兵要约收购公司股份的第一次提示性公告，1月30日股价下跌0.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607423000","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607423000?lang=zh_cn&edition=full","pubTime":"2026-01-30 23:16","pubTimestamp":1769786175,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，多瑞医药报收于62.15元，较前一交易日下跌0.29%，最新总市值为49.72亿元。多瑞医药于2026年1月30日披露《关于王庆太、曹晓兵要约收购公司股份的第一次提示性公告》。公告显示，王庆太、曹晓兵以要约方式收购多瑞医药部分股份，要约价格为32.07元/股，预定收购19,440,000股，其中王庆太拟收购17,600,000股，曹晓兵拟收购1,840,000股。截至2026年1月29日，王庆太和曹晓兵分别已有1户股东净预受对应全部拟收购股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000048194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2607097020","title":"核心产品销量及售价大幅下滑，多瑞医药2025年净利润预亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2607097020","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607097020?lang=zh_cn&edition=full","pubTime":"2026-01-30 16:28","pubTimestamp":1769761680,"startTime":"0","endTime":"0","summary":"1月29日晚间，多瑞医药发布2025年业绩预告，报告期内预计归属于上市公司股东的净利润亏损7624.49万元-9911.83万元，同比下滑21.67%-58.17%。主要销售品种醋酸钠林格注射液受集采影响销量和售价大幅下滑是当前影响业绩的主要原因之一。但从多瑞医药2025年业绩预告来看，该核心产品虽然大幅降价进入集采，但2025年销量依然大幅下降，并未实现“以价换量”，这也导致了多瑞医药2025年度主营业务收入规模及毛利水平大幅下降。","market":"hk","thumbnail":"https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/1/wangl882026130166242889471.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/1/wangl882026130166242889471.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1769761717169764.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1769761717169764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["301075"],"gpt_icon":0},{"id":"2607363860","title":"多瑞医药（301075）披露2025年度业绩预告，1月29日股价下跌4.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607363860","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607363860?lang=zh_cn&edition=full","pubTime":"2026-01-29 22:44","pubTimestamp":1769697853,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，多瑞医药报收于62.33元，较前一交易日下跌4.71%，最新总市值为49.86亿元。近日，西藏多瑞医药股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润亏损7,624.49万元至9,911.83万元，较上年同期亏损增加21.67%至58.17%；扣除非经常性损益后的净利润亏损8,224.87万元至10,692.33万元。业绩下滑主要因主营产品醋酸钠林格注射液在国家集采中标后销售价格及收入大幅下降，以及子公司四川多瑞虽收入增长但仍处于亏损状态。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900043871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2603637648","title":"股市必读：1月13日多瑞医药发生1笔大宗交易 成交金额696.13万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603637648","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603637648?lang=zh_cn&edition=full","pubTime":"2026-01-14 03:40","pubTimestamp":1768333220,"startTime":"0","endTime":"0","summary":"截至2026年1月13日收盘，多瑞医药报收于55.69元，下跌0.73%，换手率1.55%，成交量1.24万手，成交额7020.52万元。当日关注点来自交易信息汇总：1月13日主力与游资资金均呈净流出，散户资金净流入644.52万元。大宗交易1月13日多瑞医药发生1笔大宗交易，成交金额696.13万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400002908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2602054631","title":"多瑞医药（301075）披露关于要约收购提示性公告期满90日的说明，1月12日股价上涨0.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602054631","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602054631?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:27","pubTimestamp":1768228033,"startTime":"0","endTime":"0","summary":"公司于近日发布《王庆太、曹晓兵关于要约收购提示性公告期满90日的说明》。公告显示，王庆太、曹晓兵及其一致行动人崔子浩拟通过协议转让方式取得多瑞医药控制权，并于2025年10月14日披露要约收购报告书摘要。截至本说明出具日，距提示性公告已满90日，协议转让股份过户已完成，124,688,160元履约保证金已存入指定账户。要约收购报告书将尽快披露，本次要约收购尚未生效，存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200037373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2602374006","title":"多瑞医药（301075）披露关于注销募集资金专项账户的公告，1月9日股价下跌1.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602374006","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602374006?lang=zh_cn&edition=full","pubTime":"2026-01-09 22:40","pubTimestamp":1767969628,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，多瑞医药报收于55.87元，较前一交易日下跌1.64%，最新总市值为44.7亿元。该股当日开盘57.52元，最高57.52元，最低55.42元，成交额达4373.88万元，换手率为0.98%。公司于近日发布公告称，西藏多瑞医药股份有限公司因募集资金已按规定使用完毕，为降低管理成本，决定注销全部募集资金专项账户。截至目前，8个募集资金专户均已注销，相关监管协议同步终止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900041289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2593485029","title":"多瑞医药（301075）披露回购股份集中竞价减持计划，12月22日股价下跌1.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593485029","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593485029?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:55","pubTimestamp":1766397336,"startTime":"0","endTime":"0","summary":"截至2025年12月22日收盘，多瑞医药报收于50.0元，较前一交易日下跌1.77%，最新总市值为40亿元。公司近日发布公告称，西藏多瑞医药股份有限公司计划以集中竞价方式出售已回购股份，拟出售数量不超过1,044,500股，占公司总股本的1.31%，实施期限为2026年1月14日至2026年7月13日。本次出售不会导致公司总股本和控制权变化。公司已于2024年4月30日完成前述股份的回购，回购金额总计20,983,265.41元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200022907.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2592169808","title":"多瑞医药(301075.SZ)拟出售不超104.45万股已回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2592169808","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592169808?lang=zh_cn&edition=full","pubTime":"2025-12-19 19:41","pubTimestamp":1766144482,"startTime":"0","endTime":"0","summary":"智通财经APP讯，多瑞医药 公告，公司董事会审议通过了《关于回购股份集中竞价减持计划的议案》，根据公司于2024年2月8日披露的《回购报告书》之用途约定，同意公司以集中竞价方式出售已回购股份,实施期限为自本公告披露之日起15个交易日后的6个月内，本次拟出售回购股份不超过104.45万股，占公司总股本的1.31%，出售价格根据二级市场价格确定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383896.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","301075"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774391763669,"stockEarnings":[{"period":"1week","weight":-0.0591},{"period":"1month","weight":0.2566},{"period":"3month","weight":0.4817},{"period":"6month","weight":0.8934},{"period":"1year","weight":2.7024},{"period":"ytd","weight":0.3074}],"compareEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.0492},{"period":"3month","weight":-0.0151},{"period":"6month","weight":0.0073},{"period":"1year","weight":0.1517},{"period":"ytd","weight":-0.0221}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"西藏多瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"6361人(较上一季度减少16.60%)","perCapita":"12576股","listingDate":"2021-09-29","address":"西藏自治区昌都市卡若区经济技术开发区A区创业大道9号","registeredCapital":"8000万元","survey":" 西藏多瑞医药股份有限公司的主营业务是化学药品制剂及中间体、原料药的研发、生产和销售。公司的主要产品是制剂、中间体、原料药。","listedPrice":27.27},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"多瑞医药(301075)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供多瑞医药(301075)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"多瑞医药,301075,多瑞医药股票,多瑞医药股票老虎,多瑞医药股票老虎国际,多瑞医药行情,多瑞医药股票行情,多瑞医药股价,多瑞医药股市,多瑞医药股票价格,多瑞医药股票交易,多瑞医药股票购买,多瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"多瑞医药(301075)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供多瑞医药(301075)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}